Goal is to decrease drug candidate failures through improved ADME Analysis.
Applied Biosystems and MDS Sciex launched a new software development initiative to improve the abilities of pharmaceutical companies to determine drug candidate viability early in the development pipeline.
To help lower the costly drug-candidate failure rate within the pharmaceutical industry, Applied Biosystems/MDS SCIEX’s software will focus on improving the timeliness and accuracy of information generated during ADME testing of the substances that can be developed into drugs.
Applied Biosystems/MDS SCIEX is collaborating with Sound Analytics and Pfizer to design these software applications. Sound Analytics will provide expertise in early ADME software development to complement Applied Biosystems/MDS SCIEX’s expertise in drug research tools and software-based automation. Pfizer will provide the guidance to shape the requirements for the new ADME software applications.
